The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 30)
PPMI Data Challenge, 2016
Multivariate Prediction of Parkinson's Disease Clinical Progression (2016 PPMI Data Challenge Winner)
Parkinson's disease (PD) is heterogeneous in both clinical representation and prognosis, as indicated by a large diversity of rates of progression in motor as well as non-motor symptoms. It could therefore be helpful to have well-characterized and distinct subtypes of Parkinson's disease slow and fast clinical progression and have early indicators of the clinical progression rate f...
Researchers: Duygu Tosun-Turgut, PhD
Rapid Response Innovation Awards, 2014
We recently reported a new, practical approach to rate segmental progression of cardinal motor symptoms in Parkinson's disease (PD) at early stages. We computed four new scores — the Bradykinesia Segmental Score, the Tremor Segmental Score, the Rigidity Segmental Score and the Combined Segmental Score —evaluating the anatomical spread of the cardinal motor symptoms of PD on th...
Research Grant, 2014
Apomorphine is a drug that is used to control "off" episodes in people with Parkinson's disease. At present, the drug is given by injection under the skin and starts to relieve symptoms within 20-30 minutes. APL-130277 is a new formulation of apomoprhine that is given as a thin-strip film that is placed under the tongue. APL-130277 appears to work as quickly as t...
Researchers: Albert Agro, PhD
Improved Neuromodulation Approaches, 2014
The side effects of deep brain stimulation (DBS) in Parkinson's disease are related to overstimulation of the brain target structure and neighboring regions. This clinical study seeks to improve outcomes by controlling the direction of the electrical current in the brain using a novel directional DBS electrode lead. This approach offers more precise current delivery, require...
Researchers: André Mercanzini, PhD
Research Grant, 2014
The loss of glutathione in the brain of individuals with PD occurs years before the onset of motor symptoms. Glutathione has been proposed as neuroprotective therapy in PD for decades, but the therapy has been limited by the lack or oral availability and the invasiveness of intravenous administration. Recently, a Phase I Study of glutathione nasal spray concluded the therapy is sa...